Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Exclusivity Standoff

This article was originally published in SRA

  • News

Executive Summary

Policy on `first' ANDAs for different patents on the same product

You may also be interested in...



Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19

Adaptive chief medical officer Lance Baldo talked to Medtech Insight about Adaptive Biotechnologies' plans to detect prior infection using T-cells obtained from blood samples.

Executives On The Move: Genmab Promotes New CMO, BiondVax And Sprint Bioscience Pick Up New CEOs

Three new directors at Tenax Therapeutics, and a flurry of CMO and CFO appointments.

180 Life Sciences Is Looking To Repurpose Biosimilars

US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.

Table

View full table

Tags:
UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By